Revance Therapeutics Inc (NAS:RVNC)
$ 2.7 -0.2 (-6.9%) Market Cap: 282.01 Mil Enterprise Value: 480.72 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 59/100

Revance Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript

Jun 12, 2023 / 03:40PM GMT
Release Date Price: $29.55 (-1.07%)
Chris Shibutani;Mark J. Foley
Goldman Sachs Group, Inc., Research Division - Research Analyst

Good morning, everybody. Welcome to the 44th Annual Goldman Sachs Healthcare Conference. We're really pleased to kick off this day with a whole variety of companies across the spectrum. Here today, we're joined by Revance. Mark, Dustin, thank you very much for joining us. Looking forward to a discussion.

So much has happened over the past 18 months, let's call it, right, for the company in terms of just the extreme scope and what not. I think people have heard a lot from the both of you. I always like to make these conversations a little bit about making sure that we understand the people behind this and I think people maybe don't understand.

So just a little snapshot on your personal journey and one of the things about this business, the aesthetic side, is like everybody came from the same nest at some point. So there's a lot of interdigitation, et cetera. I think it'd be interesting to hear a little bit about your professional journey. We'll start with you, Mark.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot